Cargando…
p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation.
Forty-two patients with hepatocellular carcinoma (HCC) were resected and their tumours were analysed for p53 mutations by GC-clamped denaturing gradient gel electrophoresis (DGGE), single-strand conformation polymorphism (SSCP) and gene sequencing. All the exons have been analysed in this study. Eig...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2149958/ https://www.ncbi.nlm.nih.gov/pubmed/9514057 |
_version_ | 1782144558718517248 |
---|---|
author | Honda, K. Sbisà , E. Tullo, A. Papeo, P. A. Saccone, C. Poole, S. Pignatelli, M. Mitry, R. R. Ding, S. Isla, A. Davies, A. Habib, N. A. |
author_facet | Honda, K. Sbisà , E. Tullo, A. Papeo, P. A. Saccone, C. Poole, S. Pignatelli, M. Mitry, R. R. Ding, S. Isla, A. Davies, A. Habib, N. A. |
author_sort | Honda, K. |
collection | PubMed |
description | Forty-two patients with hepatocellular carcinoma (HCC) were resected and their tumours were analysed for p53 mutations by GC-clamped denaturing gradient gel electrophoresis (DGGE), single-strand conformation polymorphism (SSCP) and gene sequencing. All the exons have been analysed in this study. Eight of 12 HCCs with cirrhosis due to viral hepatitis and the two patients with sarcomatoid changes displayed p53 mutations. In contrast, no mutation was observed in the fibrolamellar variant (n = 9), non-cirrhotics (n = 13) and alcoholic cirrhosis (n = 6). The mutations observed were in exons 5-8. Two mutations were observed in codons 136 and 213 as well as a T insertion between residues 156 and 157 (exon 5) and these are reported for the first time in HCC. Likewise, the silent mutation polymorphism in codon 213 was noticed in 3 of the 42 patients. Survival analysis of these patients after surgery showed the mean and median survival in patients with wild-type p53 to be 60 and 43 months respectively. In the group with p53 mutations, the mean and median survival was 15 and 12 months. The difference was statistically significant (P= 0.003). IMAGES: |
format | Text |
id | pubmed-2149958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1998 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-21499582009-09-10 p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Honda, K. Sbisà , E. Tullo, A. Papeo, P. A. Saccone, C. Poole, S. Pignatelli, M. Mitry, R. R. Ding, S. Isla, A. Davies, A. Habib, N. A. Br J Cancer Research Article Forty-two patients with hepatocellular carcinoma (HCC) were resected and their tumours were analysed for p53 mutations by GC-clamped denaturing gradient gel electrophoresis (DGGE), single-strand conformation polymorphism (SSCP) and gene sequencing. All the exons have been analysed in this study. Eight of 12 HCCs with cirrhosis due to viral hepatitis and the two patients with sarcomatoid changes displayed p53 mutations. In contrast, no mutation was observed in the fibrolamellar variant (n = 9), non-cirrhotics (n = 13) and alcoholic cirrhosis (n = 6). The mutations observed were in exons 5-8. Two mutations were observed in codons 136 and 213 as well as a T insertion between residues 156 and 157 (exon 5) and these are reported for the first time in HCC. Likewise, the silent mutation polymorphism in codon 213 was noticed in 3 of the 42 patients. Survival analysis of these patients after surgery showed the mean and median survival in patients with wild-type p53 to be 60 and 43 months respectively. In the group with p53 mutations, the mean and median survival was 15 and 12 months. The difference was statistically significant (P= 0.003). IMAGES: Nature Publishing Group 1998-03 /pmc/articles/PMC2149958/ /pubmed/9514057 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Honda, K. Sbisà , E. Tullo, A. Papeo, P. A. Saccone, C. Poole, S. Pignatelli, M. Mitry, R. R. Ding, S. Isla, A. Davies, A. Habib, N. A. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. |
title | p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. |
title_full | p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. |
title_fullStr | p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. |
title_full_unstemmed | p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. |
title_short | p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. |
title_sort | p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2149958/ https://www.ncbi.nlm.nih.gov/pubmed/9514057 |
work_keys_str_mv | AT hondak p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation AT sbisae p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation AT tulloa p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation AT papeopa p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation AT sacconec p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation AT pooles p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation AT pignatellim p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation AT mitryrr p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation AT dings p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation AT islaa p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation AT daviesa p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation AT habibna p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation |